How to screen for colon cancer

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The biology of colorectal cancer provides a unique opportunity for early detection and prevention. There is now evidence that screening of asymptomatic average-risk individuals over 50 years of age can reduce mortality resulting from colorectal cancer. New recommendations from the US Preventive Services Task Force endorse screening with fecal occult blood tests or sigmoidoscopy. The best method for population screening remains uncertain. The cost of screening is an important issue in the development of public policy. This review discusses the various screening options, examines the 'downstream' effects of screening, and reviews the anticipated costs and effectiveness. Ultimately, the effectiveness of any screening program depends on patient compliance. Further research is needed to determine the best methods of enhancing patient adherence to a screening program.

Original languageEnglish (US)
Pages (from-to)163-172
Number of pages10
JournalAnnual Review of Medicine
Volume49
DOIs
StatePublished - 1998

Fingerprint

Patient Compliance
Colonic Neoplasms
Colorectal Neoplasms
Screening
Sigmoidoscopy
Occult Blood
Hematologic Tests
Advisory Committees
Public Policy
Cost-Benefit Analysis
Costs and Cost Analysis
Mortality
Research
Population
Costs
Blood

Keywords

  • Cost effectiveness
  • Epidemiology
  • Fecal occult blood test
  • Sigmoidoscopy

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Cite this

How to screen for colon cancer. / Lieberman, David.

In: Annual Review of Medicine, Vol. 49, 1998, p. 163-172.

Research output: Contribution to journalArticle

@article{62d1c2e1ff9844439ca63b01e0e0ff0e,
title = "How to screen for colon cancer",
abstract = "The biology of colorectal cancer provides a unique opportunity for early detection and prevention. There is now evidence that screening of asymptomatic average-risk individuals over 50 years of age can reduce mortality resulting from colorectal cancer. New recommendations from the US Preventive Services Task Force endorse screening with fecal occult blood tests or sigmoidoscopy. The best method for population screening remains uncertain. The cost of screening is an important issue in the development of public policy. This review discusses the various screening options, examines the 'downstream' effects of screening, and reviews the anticipated costs and effectiveness. Ultimately, the effectiveness of any screening program depends on patient compliance. Further research is needed to determine the best methods of enhancing patient adherence to a screening program.",
keywords = "Cost effectiveness, Epidemiology, Fecal occult blood test, Sigmoidoscopy",
author = "David Lieberman",
year = "1998",
doi = "10.1146/annurev.med.49.1.163",
language = "English (US)",
volume = "49",
pages = "163--172",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - How to screen for colon cancer

AU - Lieberman, David

PY - 1998

Y1 - 1998

N2 - The biology of colorectal cancer provides a unique opportunity for early detection and prevention. There is now evidence that screening of asymptomatic average-risk individuals over 50 years of age can reduce mortality resulting from colorectal cancer. New recommendations from the US Preventive Services Task Force endorse screening with fecal occult blood tests or sigmoidoscopy. The best method for population screening remains uncertain. The cost of screening is an important issue in the development of public policy. This review discusses the various screening options, examines the 'downstream' effects of screening, and reviews the anticipated costs and effectiveness. Ultimately, the effectiveness of any screening program depends on patient compliance. Further research is needed to determine the best methods of enhancing patient adherence to a screening program.

AB - The biology of colorectal cancer provides a unique opportunity for early detection and prevention. There is now evidence that screening of asymptomatic average-risk individuals over 50 years of age can reduce mortality resulting from colorectal cancer. New recommendations from the US Preventive Services Task Force endorse screening with fecal occult blood tests or sigmoidoscopy. The best method for population screening remains uncertain. The cost of screening is an important issue in the development of public policy. This review discusses the various screening options, examines the 'downstream' effects of screening, and reviews the anticipated costs and effectiveness. Ultimately, the effectiveness of any screening program depends on patient compliance. Further research is needed to determine the best methods of enhancing patient adherence to a screening program.

KW - Cost effectiveness

KW - Epidemiology

KW - Fecal occult blood test

KW - Sigmoidoscopy

UR - http://www.scopus.com/inward/record.url?scp=0031980742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031980742&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.49.1.163

DO - 10.1146/annurev.med.49.1.163

M3 - Article

C2 - 9509256

AN - SCOPUS:0031980742

VL - 49

SP - 163

EP - 172

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -